S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$14.56
0.00 (0.00%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.43
$14.64
50-Day Range
$12.42
$14.87
52-Week Range
$12.28
$15.36
Volume
2.37 million shs
Average Volume
2.76 million shs
Market Capitalization
$45.15 billion
P/E Ratio
26.96
Dividend Yield
3.71%
Price Target
$24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
64.8% Upside
$24.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.77mentions of Takeda Pharmaceutical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

167th out of 1,023 stocks

Pharmaceutical Preparations Industry

61st out of 501 stocks

TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

Takeda H1 Profit Down, Revenues Rise; Lifts FY22 Outlook - Quick Facts
Takeda: CHMP Recommends Approval Of Dengue Vaccine Candidate, TAK-003
EU regulator backs Takeda's dengue vaccine
EU regulator recommends clearing Takeda's dengue vaccine
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings
10/27/2022
Today
12/06/2022
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+64.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$2.05 billion
Pretax Margin
5.86%

Debt

Sales & Book Value

Annual Sales
$31.79 billion
Cash Flow
$3.52 per share
Book Value
$16.31 per share

Miscellaneous

Outstanding Shares
3,100,722,000
Free Float
3,099,482,000
Market Cap
$45.15 billion
Optionable
Optionable
Beta
0.69

Social Links


Key Executives

  • Mr. Christophe Weber (Age 56)
    Pres, CEO & Representative Director
    Comp: $4.02M
  • Mr. Constantine Saroukos (Age 51)
    CFO & Representative Director
    Comp: $2.4M
  • Dr. Andrew S. Plump (Age 57)
    Pres of R&D and Representative Director
    Comp: $2.28M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 65)
    Member of Management Board
  • Salvatore Alesci
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi
    Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci (Age 44)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Fin.













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

4 brokers have issued 12 month target prices for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $24.00 to $24.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 64.8% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2022?

Takeda Pharmaceutical's stock was trading at $13.63 at the start of the year. Since then, TAK shares have increased by 6.8% and is now trading at $14.56.
View the best growth stocks for 2022 here
.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,550,000 shares, an increase of 39.1% from the October 31st total of 3,990,000 shares. Based on an average daily volume of 3,020,000 shares, the short-interest ratio is presently 1.8 days. Approximately 0.2% of the company's shares are short sold.
View Takeda Pharmaceutical's Short Interest
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our TAK earnings forecast
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its quarterly earnings results on Thursday, October, 27th. The company reported $0.52 earnings per share (EPS) for the quarter. The business earned $7.26 billion during the quarter. Takeda Pharmaceutical had a net margin of 5.60% and a trailing twelve-month return on equity of 12.76%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.54 per share and currently has a dividend yield of 3.71%. The dividend payout ratio is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of $3.80-$3.80 for the period. The company issued revenue guidance of $28.46 billion-$28.46 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (0.13%), Renaissance Technologies LLC (0.09%), BlackRock Inc. (0.07%), Brandes Investment Partners LP (0.06%), Van ECK Associates Corp (0.06%) and Barclays PLC (0.05%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $14.56.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $45.15 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.54 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 12/7/2022 by MarketBeat.com Staff